glp-1 receptor antagonist glp-1_analogs [TUSOM Glucagon-like peptide-1 receptor - Wikipedia

However, there are specific criteria for eligibility

In the Phase 3 TRIUMPH-1 trial reported May 21, 2026, the 12 mg arm produced mean body-weight reduction of 28.3% at 80 weeks, with extension data reaching 30.3% at 104 weeks [1][2]

Individuals with PsA are more likely to be obese compared to those with RA, psoriasis, and the general population[36]

Conversely, the American Gastroenterological Association (AGA) suggests proceeding with planned procedures for patients adhering to standard pre-procedure precautions

It also promotes thermogenesis, meaning researchers may observe increased body temperature or sweating at higher doses